Linezolid Susceptibility in Europe for 2010: ZAAPS Program (5,532 strains)

RN JONES, JE ROSS, HS SADER, DJ FARRELL, RE MENDES
JMI Laboratories, North Liberty, Iowa, USA

ABSTRACT

Objectives: To report the most recent full-year of interest in ZE (2010) ZE susceptibility (ZAAPS Program) monitoring (European (EU) medical centers) involving a total of 5,532 Gram-positive organisms were collected during the year (prevalence design) in 39 hospitals in 17 countries representing 15 European (EU) medical centers. This is the final year for this sample for this central laboratory-based study.

Methods: All susceptibility (S) tests were performed using the standard broth microdilution methods, using validated panels of the National Institute for Antimicrobial Resistance (NIAMR) in the UK. Clinical samples were obtained from patients suspected of having a particular type of infection. MIC values for LZD were 0.5, 1 or 2 mg/L. No LZD-R (minimum inhibitory concentration [MIC] ≥4 mg/L) resistance strains were detected.

RESULTS

The year 2010 ZAAPs organization for Europe was expanded from 10 to 17 countries (39 sites) and increased to 5,532 strains. The overall linezolid resistance rate was only 0.14%. The resistance rates (Table 1) were low among all the major pathogens, including MR-CoNS (0.5%) and S. epidermidis (0.3%). No LZD-R (MIC ≥4 mg/L) resistance strains were detected.

The overall linezolid resistance rate was only 0.14% and these data suggest no development of the drug resistance signals (Table 1). In vitro surveillance programs (ZAAPS, ECOGID, and others) have evolved into valuable sources of epidemiological and microbial information on linezolid and other agents.

CONCLUSIONS

In vitro surveillance programs (ZAAPS, ECCMID, ECOGID, and others) have evolved into valuable sources of epidemiological and microbial information on linezolid and other agents.

REFERENCES

12. The overall linezolid resistance rate was only 0.14% and these data suggest no development of the drug-resistant strain. This study was sponsored by Pfizer Inc., Specialty Care Business Unit, Collegeville, PA, USA.

ACKNOWLEDGEMENT

This study was sponsored by Pfizer Inc., Specialty Care Business Unit, Collegeville, PA, USA.